Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Merck stock (NYSE: MRK ... compared to $25 billion in 2023. Secondly, the next best-selling product – Gardasil – faced headwinds in China, resulting in its sales falling in the recent quarters.

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Substack by Long-Term Pick. In this article, we will summarize ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Analysts have had mixed feelings about Merck in recent years, with concerns the company, like other big pharmaceuticals, isn't doing enough to ensure that its pipeline of products remains robust ...

Shares of Merck are sliding in early trading after ... due partly to a pause in shipments of one of its top-selling products to China Shares of Merck slid Tuesday after the drugmaker surprised ...